Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer


Abstract

Background—Ulcerative colitis associated colorectal cancer (UCACRC) has several distinctive clinicopathological and genetic features which differ from sporadic colorectal cancer (SCRC). Hypermethylation of the E-cadherin gene (CDH1) has not been described previously in colorectal cancer.

Aims—A panel of SCRC and UCACRC were investigated for mutations in CDH1, and for hypermethylation of the promoter region of CDH1.

Subjects and methods—DNA was available from 14 patients with UCACRC and from 14 with SCRC. All exons of CDH1 were amplified with the polymerase chain reaction (PCR) and screened using single strand conformational polymorphism and direct sequencing. Hypermethylation of the CDH1 promoter region was determined by methylation specific PCR following bisulphite modification, and compared with E-cadherin protein expression from a previous immunohistochemistry study.

Results—Thirteen of 28 cancers (46%) were hypermethylated in the CDH1 promoter region—eight cancers (57%) in the UCACRC group and five cancers (36%) in the SCRC group (NS)—and this correlated with reduced E-cadherin expression (p<0.05). There was a trend for methylation to be associated with a more advanced stage of cancer although this did not reach statistical significance. There were no mutations in CDH1 in either group although there were several polymorphisms.

Conclusion—We have demonstrated hypermethylation of the promoter region in CDH1 in 46% of colorectal cancers studied. There was no difference between UCACRC and SCRC groups. Just as there are specific differences in the genetic changes between UCACRC and SCRC, there is likely to be a large degree of overlap among the genetic pathways of these cancers.

Keywords: hypermethylation; promoter region; E-cadherin (CDH1); ulcerative colitis; colorectal cancer

Carcinogenesis is widely accepted as a multi-step process. At each step, genetic or epigenetic alterations occur and can give tumour cells a selective advantage to expand their clones to evolve through an independent process at the somatic cell level. Colorectal cancers differ in their age at presentation, location, histology, and prognosis. As the adenoma to carcinoma pathway is accompanied by genetic events, there may be differences in the genetic pathways involved in the pathogenesis of distinct types of colorectal cancer.

The increased cancer risk in ulcerative colitis is well documented and is directly related to a long duration of disease and an early age of onset. Ulcerative colitis associated colorectal cancers (UCACRC) have several different clinicopathological features compared with sporadic colorectal cancer (SCRC). They usually arise from flat dysplasia or a dysplastic associated lesion or mass whereas SCRC usually arise from an adenomatous polyp. UCACRC usually occurs at an earlier age, is distributed relatively evenly along the entire colon, and is found to have an anaplastic or mucinous phenotype more frequently than not. These differences have led observers to suggest a difference in the genetic pathway between UCACRC and SCRC. Although mutations in APC, K-ras, and TP53 are common in either UCACRC or SCRC, the observed mutation frequencies in these genes are somewhat lower in UCACRC. Differences in expression of p16 and Bcl-2 also hint at a different carcinogenesis pathway.

One of the features of malignancy is invasion into the stroma and surrounding tissues. One of the molecules implicated in the progress of tumour invasion is E-cadherin, a Ca2+ dependent cell-cell adhesion molecule. In normal epithelium, E-cadherin is located in the basolateral membrane along the whole length of the crypt, and this plays a significant role in the development and maintenance of epithelial tissues. E-cadherin is encoded for by the CDH1 gene which is located on chromosome 16q22. In the cytoplasm, E-cadherin binds several undercoat proteins: α and β-catenin, and γ-catenin/plakoglobin, through which it connects to the actin cytoskeleton. In addition, E-cadherin may affect the β-catenin associated intracellular signal pathway by competing with APC for binding to β-catenin. In inflamed tissue, E-cadherin expression is reduced to ensure the mobility of cells and healing of the mucosa. 

Abbreviations used in this paper: UCACRC, ulcerative colitis associated colorectal cancer; SCRC, sporadic colorectal cancer; RER, replication error; PCR, polymerase chain reaction; SSCP, single strand conformational polymorphism.
ulcer. This phenomenon is well described in inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Loss of expression and function of E-cadherin is associated with loss of differentiation and increased invasiveness in colorectal cancer.

The E-cadherin gene (CDH1) is regarded as a tumour invasion-suppressor in epithelial cells, and mutations have been described in a number of epithelial cancers, including lobular breast and diffuse gastric cancers. More recently, inactivating mutations in CDH1 have been described in human colorectal cancer cell lines. Hypermethylation in the promoter region in cancers has been described for a number of genes such as p16, VHL, and hMLH1 and is usually associated with lack of expression of corresponding proteins in cancer. It has also been shown that E-cadherin expression is silenced by hypermethylation of the CDH1 promoter region in a number of tumours, including breast, prostate, and hepatocellular carcinomas.

In this study, we have sought additional evidence that UCACRCs may develop along a different pathway to that of SCRCs by investigating if there is any difference in the incidence of mutations in CDH1 and hypermethylation of its promoter region between UCACRC and SCRC.

Material and methods
DNA from 14 UCACRCs and 14 SCRCs without a family history of colorectal cancer were accessed from the archives of the Imperial Cancer Research Fund, Oxford, UK.

The replication error (RER) status was determined by amplification of BAT26 and BAT25 with fluorescent labelled primers and polymerase chain reaction (PCR) conditions, as previously described. Essentially, 2 µl of PCR product were mixed with 0.5 µl of Rox size standard and 1 µl of formamide loading buffer, heat denatured, and quenched on ice before being electrophoresed on a 6% acrylamide sequencing gel with a 377 Prism fluorescence based semiautomated sequencer (Applied Biosystems). The sequences were compared with published sequences using Sequencer 3.0 software.

METHYLATION SPECIFIC PCR
The methylation status of the CDH1 promoter region was evaluated by performing methylation specific PCR of genomic DNA which had been purified following chemical treatment with sodium bisulphite, as described previously. Primer sequences for “unmethylated” and “methylated” methylation specific PCR of the CDH1 promoter region and PCR conditions have been described previously. PCR products were silver stained following 10% polyacrylamide gel electrophoresis. The unmethylated breast cancer cell line MDA-MA-468, and the methylated breast cancer cell lines MDA-MA-231 and MDA-MA-435 were used as relevant controls. All results were confirmed by duplicate analysis.

STATISTICS
Comparisons between the two groups were performed using the Wilcoxon rank sum test, Fisher’s exact test, or the t test using SAS software (v 6.11, SAS Institute Inc., North Carolina, USA). The relationship between promoter hypermethylation and reduced expression of E-cadherin was analysed using Fisher’s exact test and the χ² test.

Results
CLINICOPATHOLOGICAL FEATURES
Patients with UCACRC presented at a younger mean age than those with SCRC (p=0.001). There was no significant difference between the two groups for other factors: sex distribution, differentiation, stage, or RER status (table 1). UCACRC was more commonly located in the right colon although this was not statistically significant.

RER STATUS
One UCACRC and two SCRC were found to be RER+ (table 1).

GENETIC CHANGES IN CDH1
No mutation was identified in either UCACRC or SCRC. We found several polymorphisms, including intronic changes, namely single base substitutions in intron 2, intron 4, and intron 12, and a silent change at codon 692 (GCC→GCT, Ala→Ala) (table 2). All polymorphisms were found in heterozygotes. The change in intron 2 (ctggtt→ctaggt) was a novel
change and only present in the UCACRC group. This change was not present in 80 human random controls. All other changes have been described previously. Differences in the frequencies of the polymorphisms between the two groups were not statistically significant.

**METHYLATION STATUS**

All 28 cancers showed PCR products for at least one unmethylated allele. Eight of 14 UCACRC and five of 14 SCRC showed PCR products for a methylated allele (fig 1). There was no significant difference in the frequency of methylated alleles between UCACRC and SCRC. When all cases combined were divided into methylated and unmethylated groups, there were no significant differences in pathological differentiation, stage, or RER status (table 3). However, advanced stage occurred more frequently (61.5% of Duke’s C and D in UCACRC and 46.7% in SCRC) with hypermethylation but this difference was not statistically significant.

**METHYLATION STATUS AND ITS ASSOCIATION WITH E-CADHERIN PROTEIN EXPRESSION**

Previous immunohistochemistry on these samples has shown similar patterns of E-cadherin expression (and CDH1 allele loss) between UCACRC and SCRC.31 In this previous study, those cases which showed membrane staining in more than 25% of tumour cells (grade 2/3) were regarded as positive for E-cadherin expression. The immunohistochemistry data were then compared with the corresponding CDH1 promoter methylation status from this study. Hypermethylation of the promoter region of E-cadherin correlated significantly with reduced E-cadherin immunohistochemical expression (Fisher’s exact test, \( p=0.036 \); \( \chi^2 \) test, \( p=0.034 \)). Eight of 11 grade 0/1 tumours were methylated while 11 of 16 tumours were unmethylated (table 3).

### Table 1 Clinico-pathological features and methylation status of promoter region in CDH1 in ulcerative colitis associated colorectal cancer (UCACRC) and sporadic colorectal cancer (SCRC)

<table>
<thead>
<tr>
<th></th>
<th>UCACRC (n=14)</th>
<th>SCRC (n=14)</th>
<th>( p ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean (SD))</td>
<td>49 (8.4)</td>
<td>64.3 (9.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>6</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td>Left colon</td>
<td>3</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>Rectum</td>
<td>5</td>
<td>7</td>
<td>NS</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well/moderate</td>
<td>10</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>Poor</td>
<td>4</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>Duke’s A and B</td>
<td>8</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>Duke’s C and D</td>
<td>6</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td>RER status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>1</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td>–</td>
<td>13</td>
<td>12</td>
<td>NS</td>
</tr>
<tr>
<td>Methylation status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>8</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>–</td>
<td>6</td>
<td>9</td>
<td>NS</td>
</tr>
</tbody>
</table>

### Table 2 Summary of polymorphisms in CDH1 in ulcerative colitis associated colorectal cancer (UCACRC) and sporadic colorectal cancer (SCRC)

<table>
<thead>
<tr>
<th>Codon</th>
<th>Nucleotide change</th>
<th>Consequence</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>UCACRC</td>
</tr>
<tr>
<td>Intron 2</td>
<td>ctggg→ctagg</td>
<td>—</td>
<td>2 of 14</td>
</tr>
<tr>
<td>Intron 4</td>
<td>gaaa→gaaac</td>
<td>—</td>
<td>3 of 14</td>
</tr>
<tr>
<td>Intron 12</td>
<td>attcg→atcgc</td>
<td>—</td>
<td>4 of 14</td>
</tr>
<tr>
<td>692</td>
<td>GGC→GCT</td>
<td>Ala→Ala</td>
<td>10 of 14</td>
</tr>
</tbody>
</table>

Figure 1 Silver staining of methylation specific polymerase chain reaction (PCR) products following electrophoresis on an acrylamide gel. Sample pairs 1–6 are from ulcerative colitis associated colorectal cancer (UCACRC), and 7–11 are from sporadic colorectal cancer (SCRC). E-cadherin protein expression is shown as present (+; grade 2/3) or absent (−; grade 0/1). Primer sets used for PCR amplification are designated as unmethylated (U) or methylated (M), and a PCR product is shown as present (+) or absent (−). A PCR product is seen using unmethylated primers in the unmethylated breast cancer cell line, MDA-MA-468, and with methylated primers in the methylated breast cancer cell line, MDA-MA-435 (C=control). Hypermethylation of the promoter region of CDH1 correlated significantly with reduced E-cadherin immunohistochemical expression (Fisher’s exact test, \( p=0.036 \); \( \chi^2 \) test, \( p=0.034 \)). The methylated cancers that expressed E-cadherin protein may have been hemimethylated (methylation of one allele) and were therefore still able to express E-cadherin protein.
Table 4 E-cadherin expression and its relation to methylation status

| Scored semiquantitatively according to the proportion of stained tumour cells. |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Not determined |
| Methylated (13) | 0 | 8 | 1 | 4 | 0 |
| Unmethylated (15) | 1 | 2 | 7 | 4 | 1 |

Discussion

We have previously described mutations in CDH1 in 8% of colorectal cancer cell lines. In the present study we did not find any mutation in CDH1 in UCACRC or SCRC, although this may have been due to the relatively small sample numbers. Previous mutations were described in RER+ cell lines (33%), and only three of our 28 samples were RER+. However, we detected hypermethylation in the promoter region in a significant proportion of colorectal cancers. Although, hypermethylation of the promoter region of CDH1 is seen in more than 80% of papillary thyroid carcinomas, which is associated with reduced E-cadherin expression, hypermethylation of the CDH1 promoter was detected in only 46% of our samples. Fifty seven per cent of UCACRC and 36% of SCRC were hypermethylated but this difference was not statistically significant. Tumours with a hypermethylated promoter region did not have different clinicopathological features, such as advanced stage or poor differentiation. However, hypermethylation of the CDH1 promoter was significantly associated with reduced or absent expression of E-cadherin protein (p=0.036). Hypermethylation of the CDH1 promoter has not been described previously in human colorectal cancer. Yoshiura and colleagues studied a panel of human carcinoma cell lines. However, only one cell line (SW1116) originated from the colon and was found to be unmethylated in the CDH1 promoter and to express E-cadherin mRNA.

Other work has shown that hypermethylation of the promoter region of CDH1 in prostate, breast, and hepatocellular carcinoma is associated with reduced protein expression. Our results suggest that hypermethylation of the promoter region of CDH1 in colorectal cancers is associated with a reduction in E-cadherin expression. This is similar to work using paraffin sections of thyroid and hepatocellular carcinomas where CDH1 promoter methylation is associated with a reduced intensity or heterogeneous pattern of E-cadherin expression.

A PCR product was seen in all tumours with unmethylated primers, and it may be that some of our tumours were only partially methylated or hemimethylated (methylation of one allele), although this is difficult to examine as the tumours were not microdissected and are therefore contaminated with background stroma. Hence the unmethylated PCR product may be representative of this background stroma. It is also possible that there is a subpopulation of cancer cells that are hypermethylated and do not in fact express E-cadherin, but that a further subpopulation of cells with no methylation do express E-cadherin. Four cancers that were found to have a hypermethylated CDH1 promoter also had grade 3 expression (>50%) of E-cadherin protein. It is likely that these cancers were hemimethylated and were therefore still able to express E-cadherin protein. This has previously been described for the hMLH1 gene and its protein in human colorectal cancer cell lines which are not contaminated with background stroma.

Dosage effects, as a result of at least partial methylation of the CDH1 promoter reducing expression of E-cadherin, may give a selective advantage for tumour outgrowth. If gene dosage to half function did not occur, or did not give a sufficient selective advantage, a dominant negative effect would be required to reduce the level significantly below half. However, we have not identified any mutation in these samples that could perform this function. In conclusion, although we did not find mutations in CDH1, we demonstrated hypermethylation of the promoter region in CDH1 in 46% of colorectal cancers. Hypermethylation of CDH1 has not been described previously in colorectal cancer, but we have shown that this correlates significantly with reduced E-cadherin expression. This reduced expression of E-cadherin could be the basis for selecting hypermethylation of an allele during tumour progression. We have not shown a significant difference in E-cadherin expression, CDH1 mutations, or hypermethylation of its promoter between UCACRC and SCRC. Just as there are specific differences in the genetic changes between UCACRC and SCRC, there is also likely to be a large degree of overlap among the genetic pathways of these cancers.